XORTX Therapeutics Invites Shareholders to Participate Actively
XORTX Therapeutics Invites Shareholders to Participate Actively
CALGARY, Alberta – XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a prominent clinical pharmaceutical company dedicated to developing innovative therapies aimed at treating progressive kidney disease, is reaching out to its shareholders to remind them of the crucial voting deadline for its Annual General and Special Meeting (the "Meeting"). This significant event is set to take place on September 12, 2024.
Importance of Your Vote
The Board of Directors at XORTX emphasizes the importance of shareholder participation, recommending that all shareholders vote in favor of the proposed agenda items during the Meeting. Regardless of the number of shares one holds, each vote counts and plays a vital role in shaping the future of the company.
Key Agenda Items
During the Meeting, shareholders will deliberate on a variety of pressing matters, which include:
- Determining the number of directors to be set at seven;
- Electing the board of directors;
- Appointing the auditor;
- Approving the amended Stock Option Plan for XORTX.
Institutional Shareholder Services Inc. (ISS), a respected independent proxy advisory firm, has recommended that shareholders vote “FOR” all the proposed resolutions, reinforcing the board's stance.
Meeting Details
The Meeting will convene at 10:00 AM (Calgary Time) on September 12, 2024, at the corporate offices located at 3710 – 33rd Street NW in Calgary. Shareholders are encouraged to review all relevant documents and updates prior to the Meeting.
Voting Deadline
The deadline for proxy voting is set for 10:00 AM (Calgary time) on September 10, 2024. It’s imperative to ensure your voice is heard by participating in the voting process ahead of this deadline.
Contact for Voting Assistance
For any inquiries regarding the Meeting's agenda or assistance with voting, shareholders can reach out to XORTX's proxy solicitation agent, Laurel Hill Advisory Group:
North American Toll Free: 1-877-452-7184
International: +1-416-304-0211
Email: assistance@laurelhill.com
About XORTX Therapeutics Inc.
XORTX is advancing two clinical products: XRx-008, aimed at treating autosomal dominant polycystic kidney disease (ADPKD), and XRx-101, targeting acute kidney injury related to Coronavirus / COVID-19. Furthermore, they have another pre-clinical program, XRx-225, focused on Type 2 Diabetic Nephropathy. The company is committed to pioneering treatments that address abnormal purine metabolism and xanthine oxidase activity to effectively reduce uric acid levels. XORTX strives to enhance the quality of life and health outcomes for patients dealing with these challenging conditions.
For more information, please contact:
Allen Davidoff, CEO
Email: adavidoff@xortx.com or call +1 403 455 7727
Nick Rigopulos, Director of Communications
Email: nick@alpineequityadv.com or call +1 617 901 0785
Kim Golodetz, LHA Investor Relations
Email: kgolodetz@lhai.com or call +1 212 838 3777
Frequently Asked Questions
What date is the XORTX Therapeutics shareholder meeting?
The meeting is scheduled for September 12, 2024.
What are the main agenda items for the meeting?
Shareholders will vote on matters such as director election, auditor appointment, and approving the amended Stock Option Plan.
Who is advising on the proxy voting?
Institutional Shareholder Services Inc. (ISS) has recommended shareholders vote in favor of all proposed resolutions.
What is the deadline for submitting a vote?
Proxy voting must be completed by 10:00 AM Calgary time on September 10, 2024.
How can shareholders get assistance regarding the meeting?
Shareholders can contact Laurel Hill Advisory Group for assistance at 1-877-452-7184 or via email at assistance@laurelhill.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.